drugset / Trial / NCT02447185

25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial

NCT02447185

RandomizedParallel-groupSingle-blindPrevention

Summary

Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR. Anti-vascular endothelial growth factor (anti-VEGF) can be used as an adjuvant therapy which can make operation more easy.

Timeline

Start
2015-06
Primary completion
2020-12
Completion
2021-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.2 mg Intravitreal
Subject Triamcinolone Acetonide Other / unclassified 1 mg Intravitreal